|
Entod Pharmaceuticals eyes 40% growth for FY2022
|
|
Yash Ved, Mumbai
October 16 , 2021
|
|
|
Entod Pharmaceuticals, a leading research based pharmaceutical company, is eyeing 40% growth for FY2022 and expanding sales field force to help promote 200 plus products in the Indian and global markets.
The company stated that it is planning to expand in ophthalmic surgical segment over the next 2-3 years with the launch of HyTek Division to establish presence across the domestic and international markets.
“Our HyTek division will especially focus on the products which are required during ophthalmic surgical procedures like cataracts, refractive surgeries etc. The HyTek division has been launched in Mumbai and subsequent extension plans are in progress for other metro and sub-metro cities,” the company said.
The company is planning to have over 150+ field forces/employees within the next 6 months for medical cosmetics and ophthalmic surgical segments and aiming to have 1,000+ field force by the end of the financial year.
"We have also introduced Phenocaine Plus intracameral mydriatics injection which helps to achieve rapid and stable pupillary dilatation without using preoperative dilating eye drops and sustained intraocular anaesthesia for pain-free surgery and better surgical outcomes. Other than that, our research team has come up with an innovative micronized ocular suspension technology that offers better formulation stability, greater bioavailability, more precise dosing and reduced ocular irritation. Our specialty range includes eye drops, eye ointments, eye gels, intracameral injectables, ear drops, nasal spray, creams, ointments, lotions and solid & liquid orals designed for global supply," stated Nikkhil K Masurkar, executive director, Entod Pharmaceuticals.
The company added that it has entered into the market of medical cosmetics through a joint-venture with NuSkin London. NuSkin London is a research initiative of Entod Research Cell UK Ltd, which aims to improve skin formulation research and create innovative dermatological solutions.
Medical cosmetics are now available in selected markets and expanded in the ophthalmic surgical segment by launching HyTek Division, which will deal with surgical products, the company added.
“With a market size of around $45 billion in FY21, Indian pharmaceutical industry globally ranks third in terms of volume and thirteenth in terms of value. The main factors responsible for the growth of the industry are ability to utilise the opportunity available for Indian pharma companies due to expiry of the patent drugs across the globe, adoption of different strategies to de-risk from dependency on China for raw materials, receding of regulatory risks, increasing PE investments and strong fundamentals of the industry,” stated Masurkar.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|